Abnormal long COVID PET/MR findings linked to future cardiac and pulmonary diseases

Reston, VA (July 21, 2025)—Long COVID patients with abnormal cardiopulmonary PET/MR findings may be more likely to develop heart and lung diseases, according to new research published in the July issue of The Journal of Nuclear Medicine. The study—which included the largest cohort of long COVID subjects with cardiopulmonary symptoms with the longest follow-up duration—suggests that abnormal cardiopulmonary PET/MR should be considered a risk factor for future cardiac and pulmonary disease and that closer monitoring is warranted in these patients.

To date, the COVID pandemic has seen more than 400 million people infected worldwide, with more than 80 million infections and approximately one million deaths in the United States. Long COVID has emerged as a major public health challenge, affecting between one-third and two-thirds of patients many months after recovery from the initial COVID infection.

“Unfortunately, the long-term consequences of long COVID remain unknown,” said Maria Giovanna Trivieri, MD, PhD, FACC, FRCPC, associate professor of medicine (cardiology) and associate professor of radiology at the Icahn School of Medicine, Cardiovascular Research Institute, Biomedical and Molecular Imaging Institute, in New York, New York. “In this study we sought to use advanced cardiopulmonary imaging to assess for evidence of cardiac and lung abnormalities, vascular injury, and inflammation in patients with long COVID.”

The study included 98 patients with a history of COVID infection, persistent cardiopulmonary symptoms nine to 12 months after initial infection, and a clinical assessment compatible with long COVID. A control group that included subjects with a history of severe COVID but without cardiopulmonary symptoms at recruitment was also characterized. Both groups underwent cardiopulmonary ¹⁸F-FDG PET/MRI and dual-energy CT (DECT) of the lungs. A plasma protein analysis was also conducted for a subgroup of patients.

PET/MRI was abnormal for 57 percent of subjects, showing myocardial, pericardial, periannular, and vascular uptake, none of which was present on the PET/MR scans of the control group. Ninety percent of subjects presented abnormalities in DECT, including pulmonary infiltrates and abnormal perfusion. Analysis of plasma protein concentrations showed significant differences between the long COVID and the control groups, and the plasma protein profile was significantly different among long COVID patients with abnormal and normal PET/MR scans. During the four-year follow-up period, PET/MR abnormalities were more frequent in patients that subsequently developed heart failure, mitral regurgitation and pulmonary hypertension.

“The results of the study should raise awareness in the clinicians to elicit a proper history that includes prior COVID infection and long COVID symptoms,” stated Ana Devesa, MD, PhD, former postdoctoral fellow at Biomedical and Molecular Imaging Institute, in New York, and group leader at Centro Nacional de Investigaciones Cardiovasculares (CNIC) in Madrid, Spain. “If a temporal link is identified between symptoms and timing of infection, further evaluation might be appropriate."

The authors of “Prevalence of Persistent Cardiovascular and Pulmonary Abnormalities on PET/MRI and DECT Imaging in Long COVID Patients” include Maria Giovanna Trivieri, Icahn School of Medicine at Mount Sinai, Mount Sinai Fuster Heart Hospital, New York, New York, BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, and Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Ana Devesa, BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, and Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain; Philip M. Robson, Busra Cangut, Audrey Kaufman, Renata Pyzik, Valentin Fauveau, Edwin Yoo, Sarayu Huang, Claudia Calcagno, Venkatesh Mani, Sahityasri Thapi, and Zahi A. Fayad, BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Jamie Wood, Abilities Research Center, Icahn School of Medicine at Mount Sinai, New York, New York; Sonali Bose and Aaron Shpiner, Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; Steve Liao, Johanna Contreras, and Donna Mancini, Icahn School of Medicine at Mount Sinai, Mount Sinai Fuster Heart Hospital, New York, New York; Kai Nie and Seunghee Kim-Schulze, Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York, and Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Sacha Gnjatic, Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York, Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, and Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Miriam Merad, Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, New York, Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York, Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, and Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Munir Ghesani, Division of Nuclear Medicine, Icahn School of Medicine at Mount Sinai, New York; David Putrino, Abilities Research Center, Icahn School of Medicine at Mount Sinai, New York, New York, and Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, New York; Adam Jacobi, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, New York; and Charles Powell, Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain.

Visit the JNM website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn.

###

Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or rmaxey@snmmi.org.

About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed 15 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.

JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.